Insmed reported $-94236000 in Pre-Tax Profit for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acelrx Pharmaceuticals ACRX:US $ -8.67M 0.76M
Alimera Sciences ALIM:US $ -5.96M 1.82M
Biomarin Pharmaceutical BMRN:US $ 26.19M 92.76M
Cytokinetics CYTK:US $ -86.75M 56.18M
Dynavax Technologies DVAX:US $ 32.86M 67.73M
Heron Therapeutics HRTX:US $ -63.89M 9.24M
Insmed INSM:US $ -94236000 18.78M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Novartis NVS:US $ 3912M 230M
Ophthotech OPHT:US $ -34.54M 1.5M
Regeneron Pharmaceuticals REGN:US $ 1119.1M 1986M
Sarepta Therapeutics SRPT:US $ -104.15M 17.74M
Seattle Genetics SGEN:US $ -135.24M 41.73M
Ultragenyx Pharmaceutical RARE:US $ -151.76M 29.32M